ShangPharma Corp. (SHP) Misses Q1 EPS by 2c; Reaffirms Outlook

ShangPharma Corp. (NYSE: SHP) reported Q1 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $30.8 million versus the consensus estimate of $29.8 million.

ShangPharma Corp. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on ShangPharma Corp. (SHP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Citi raises Huya price target to $4.60 from $4.40
• BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance